For patients with type 2 diabetes or established cardiovascular disease, trials including SUSTAIN 6 and later outcome studies have demonstrated reduced rates of stroke, heart attack, and major adverse cardiac events with semaglutide and related drugs
These reports may reflect individual variation, concurrent factors such as rapid weight loss (which can affect skin integrity), nutritional changes, or coincidental dermatological conditions rather than a direct drug effect
A recent study found that the triple agonist retatrutide for GLP-1R, GIPR and GCGR substantially induced weight loss in obese adults, demonstrating the clinical potential of this triple agonist for obesity treatment
[51] found that linagliptin decreases aortic pulse wave velocity (PWV), a surrogate marker for arterial stiffness and early atherosclerosis, by an average of 0.91 m/s
Elevated plasma ghrelin levels in Prader-Willi syndrome
The Precision Peptide Genetic Test identifies which GLP-1 pathway dominates your weight regulation, helping PlexusDx clinicians design a personalized protocol that works withnot againstyour genetics
